In vitro diagnostics (IVD) is the technique in which medical devices and reagents are used to examine specimens such as blood, urine, stool, tissues, and other body fluids of human body for detection of diseases, conditions, and infections; in an in-vitro environment.
The Asia-Pacific IVD market is driven by rise in geriatric population and rapid expansion of government healthcare expenditure. In addition, increase in awareness of personalized medicine and preventive healthcare measures boost the market share. Furthermore, rise in prevalence of communicable and non-communicable diseases are anticipated to increase the demand of diagnosis, thereby increasing the market growth. However, stringent
government regulations associated with the safety and efficacy of IVD products is expected to hinder the growth of the market during the forecast period. The emerging economies of the Asia-Pacific regions offer lucrative growth opportunities to IVD during the forecast period. The Asia-Pacific IVD market accounted for $13,680 million in 2016, and is estimated to reach at $19,888 million by 2023, growing at a CAGR of 5.4% from 2017‐2023.
The market is segmented on the basis of product type, techniques, application, end-user, and country. By product type, the market is categorized into reagents, instruments, and software & services. On the basis of techniques, it is categorized into immunodiagnostics, blood testing, molecular diagnostics, tissue diagnostics, clinical chemistry, and other IVD techniques. Application segment covered in the study include infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and other indications. Based on end-user, it is classified into, hospitals, academic and medical schools, point of care testing, and others. Country-wise, it is analyzed across India, China, Japan, South Korea, Australia, and Rest of Asia-Pacific.
KEY BENEFITS FOR STAKEHOLDERS
KEY MARKET SEGMENTS
By Product Type
By End Users
List of players profiled in the report
Cephalosporin Market by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, and Fifth-generation), Type (Branded and Generics), Route of Drug Administration (Injection and Oral), and Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, and Sexually Transmitted Infection) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Cephalosporin is a group of semisynthetic, broad-spectrum antibiotics, which is majorly used to treat bacterial infections. It resembles penicillin and hence is used as an alternative for patients who are allergic to penicillin. It is used in the treatment of a variety of clinical conditions, including pneumonia, skin infections, strep ...
November 2017 | $5370 |View Details>>
The Global Drugs for Malaria market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) of XX% from between 2016 and 2022. This report studies the global Drugs for Malaria market, especially in North America, Europe, Asia-Pacific, South ...
November 2017 | $4960 |View Details>>
In 2016, the Asia-Pacific Drugs for Malaria market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Drugs for Malaria in Asia-Pacific market, especially in China, Japan, Korea, Taiwan, India, Australia, Indonesia, Thailand and ...
November 2017 | $4660 |View Details>>
In 2016, the Drugs for Malaria market size was xx million USD in China, and it will be xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. In China market, the top players include Cipla Guilin Pharmaceutical ...
November 2017 | $3360 |View Details>>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research